Privately-held French drugmaker Servier has announced the appointment of Nitza Thomasson as executive director, R&D Neurology.

Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. Fresh with a new brand identity ...

He is currently Executive Director Research at Servier, where he manages the research centers in France, Denmark, Hungary and ...

Servier and The World Heart Federation (WHF) have announced that the duo has taken the lead in rallying support from ...

Egypt - Servier Egypt, part of the global Servier Group, has commemorated its 70th anniversary with the opening of a new production line and the launch of the “Access Cancer Treatment (ACT) for ...